Drug facts
BrandPemfexy (Pemetrexed)
No generic version of Pemfexy is approved; the latest Pemfexy patent or exclusivity in the Orange Book runs to 02/19/2036.
Pemfexy was first approved by the FDA on 02/08/2020 under NDA 209472; the application holder is Eagle Pharmaceuticals Inc.
Holder Eagle Pharmaceuticals IncApplication NDA 209472Approved 02/08/2020
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
3,398days until the latest patent expires
ExclusivityPatent onlyOpen to generics
Today
Approved02/08/2020
Last patent02/19/2036
202120242027203020332036
- Latest patent
- 02/19/2036Pemfexy Orange Book
02Competition
- Generics
- No generic approved Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Pemfexy profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
04Product
- Application holder
- Eagle Pharmaceuticals Inc Orange Book
- Application
- NDA 209472 Orange Book
- First approved
- 02/08/2020 Orange Book
- Dosage forms
- solution
- Routes
- intravenous
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.